Last updated on July 2018

Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic subdural hematoma
  • Age: Between 50 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • On CT confirmed cSDH
  • Primary conservative treatment, based on clinical symptoms: Glasgow Coma Scale score >=14, mNIHSS score <=4 and a stable neurological deficit (no new, or progression of, symptoms between the assessment by the neurologist and the assessment by the neurosurgeon).

Exclusion Criteria:

Primary surgical treatment based on one or more of the following symptoms or parameters: medically intractable headache, midline shift >10mm, imminent death within 24 hours;

  • Structural causes for subdural haemorrhage, e.g. arachnoid cysts, cortical vascular malformations and a history of cranial surgery <1year;
  • Aneurysmal subarachnoid haemorrhage;
  • Active treatment for deep vein thrombosis, pulmonary embolism or cerebral thrombosis (secondary prophylaxis is not considered to be active treatment);
  • Active intravascular clotting or disseminated intravascular coagulation;
  • Known hypersensitivity or allergy to TXA or to any of the ingredients;
  • History of a blood coagulation disorder (hypercoagulability disorder);
  • History of severe impairment of renal function (eGFR <30ml/min or serum creatinine >150mol/L);
  • History of anaemia (haemoglobin <6mmol/L);
  • History of convulsions;
  • History of inability to safely swallow oral medication.
  • Inability to obtain informed consent from the patient or legal representative (when the patient has a depressed level of consciousness as described in paragraph 11.2), including language barrier;

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.